Last reviewed · How we verify
Sabia plaster
Sabia plaster is a transdermal patch formulation that delivers an active pharmaceutical ingredient through the skin for systemic therapeutic effect.
At a glance
| Generic name | Sabia plaster |
|---|---|
| Sponsor | Hisamitsu Farmaceutica do Brasil Ltda |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a transdermal plaster, Sabia provides sustained, controlled release of its active component across the skin barrier into systemic circulation, bypassing first-pass hepatic metabolism. This delivery method allows for prolonged therapeutic exposure with potentially improved tolerability and compliance compared to oral formulations. The specific molecular mechanism depends on the active ingredient contained within the patch formulation.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sabia plaster CI brief — competitive landscape report
- Sabia plaster updates RSS · CI watch RSS
- Hisamitsu Farmaceutica do Brasil Ltda portfolio CI